BAXTER 2026 Q1: International Strength Offsets U.S. Headwinds as EPS Non-GAAP Shine Emerges

Ticker: BAX. In its first-quarter 2026 release, Baxter International Inc. lays out a nuanced picture: revenue at roughly 2.7 billion dollars from continuing operations, a 3% gain on a reported basis but a 1% decline on an organic basis. The earnings per share tale is split between a GAAP loss on continuing operations (approximately $0.03 per share) and a healthier EPS story on a non-GAAP basis, with adjusted diluted EPS of about $0.36. Baxter also reaffirmed its revenue forecast for the full year 2026, signaling management’s guarded optimism about the year ahead.

The press release emphasizes that continuing operations exclude Baxter’s Kidney Care business, which was divested in January 2025 and is reported as discontinued operations. In other words, the headline numbers reflect a company recalibrated around its remaining core portfolio and the performance mix inside that portfolio.

The number by number: what Baxter reported

Worldwide sales from continuing operations: approximately $2.7 billion, up 3% on a reported basis, down 1% on an organic basis.
U.S. sales from continuing operations: roughly $1.44 billion, down 4% on both a reported and organic basis.
International sales from continuing operations: about $1.27 billion, up 12% on a reported basis and up 3% on an organic basis.
GAAP diluted EPS (continuing operations): a loss of about $0.03 per share.
Adjusted diluted EPS (continuing operations): about $0.36 per share.

The company reiterates its full-year 2026 financial outlook, which suggests that management sees enough momentum, particularly internationally, to support a reiterated revenue trajectory even as U.S. results soften. In addition, Baxter highlights non-GAAP financial measures and provides reconciliations in accompanying tables, underscoring the classic dual-track nature of contemporary corporate disclosures.

Management tone and what it signals

CEO Andrew Hider frames the quarter as a step toward stabilizing the business, embedding a culture of continuous improvement, and strengthening execution. The rhetoric isn’t about a dramatic turnaround; it’s about steady progression, with a nod to resilience and mission-driven focus that Baxter says serves more than 350 million patients globally each year.

The juxtaposition of a modest top-line improvement in continuing operations with an EPS narrative that includes a GAAP loss and a solid non-GAAP EPS underscores the ongoing tension many medtech players feel: cost discipline, product mix shifts, and the tricky arithmetic of withholding the Kidney Care business from the core results. Investors listening for long-run value will parse whether the earnings surprise or the EPS consensus figures align with this narrative as the year unfolds.

What it portends for Baxter and sector peers

Baxter’s international strength—10+% growth in international revenue on a reported basis, with organic growth north of the global mix—suggests that the company’s geographic diversification is quietly paying off. In a world where currency headwinds and supply-chain frictions can bite in the U.S., the company’s ability to post international gains helps cushion the overall earnings cadence.

The U.S. result, by contrast, signals a more challenging short-run environment for Baxter’s domestic operations. A 4% decline in U.S. sales, even if partially offset by international momentum, implies that Baxter’s near-term earnings trajectory will be sensitive to domestic demand, pricing dynamics, and the company’s ability to manage cost structures in a more competitive environment.

For sector peers, the quarter serves as a reminder that non-GAAP measures and the continued emphasis on margin discipline remain central to earnings narratives in medtech. Companies that can translate non-GAAP benefits into durable cash flow—while presenting GAAP results that avoid disguising structural issues—will likely attract investor attention as the sector wades through a mix of macro pressures, including currency shifts, inflationary input costs, and evolving regulatory expectations.

Baxter’s decision to reiterate its 2026 outlook signals caution and credibility at once: management wants to keep expectations intact while acknowledging the ongoing adjustments from legacy segments and divestitures. If international momentum persists and U.S. headwinds abate, the revenue forecast could lift more meaningfully over the course of the year, potentially widening the gap between GAAP and non-GAAP narratives in a way that’s constructive rather than confounding.

Risks, caveats, and what to watch next

A meaningful caveat is that the presented numbers reflect continuing operations, excluding the Kidney Care business. Investors should watch how the restatement of legacy assets and the non-GAAP reconciliations evolve as the year progresses. The press release also notes that non-GAAP measures exclude certain items and that the reconciliation to U.S. GAAP is provided, which is a standard but important reminder that the near-term earnings reality can differ from the “adjusted” narrative.

From a sector perspective, Baxter’s exposure to international markets and its ongoing emphasis on efficiency improvements may foreshadow how peers allocate capital in a landscape where growth is increasingly earned abroad and translated back into U.S. dollars. A meaningful EPS surprise here could come from stronger-than-expected international growth, improved U.S. utilization of existing assets, or cost-out actions that lift margins without sacrificing revenue.

Bottom line

Baxter’s Q1 2026 results map a careful path: steady top-line progress from continuing operations, a notable swing in GAAP versus non-GAAP earnings per share, and a reaffirmed full-year outlook that implies management sees room to navigate both foreign strength and domestic softness. For investors, the story hinges on whether the international gains can sustain momentum into the second half and whether U.S. headwinds soften as supply chains normalize and pricing actions take hold. The release’s emphasis on non-GAAP metrics and reconciliations remains a reminder that, in the fray of quarterly narratives, the real debate often centers on what the ongoing, cash-generative core looks like when the accountants finish their work.

In the broader medtech arena, Baxter’s mix, including the kidney-care legacy and its strategic realignment, will be watched by peers for clues about portfolio optimization and resilience in a year when “EPS consensus” and “revenue forecast” guidance are the currency of investor confidence.

Note: This article reflects the figures and disclosures as presented in Baxter International Inc.’s Q1 2026 release and accompanying materials. All numbers pertain to continuing operations unless noted otherwise.